| Integrative clinical and molecular characterization of translocation renal cell carcinoma Z Bakouny, A Sadagopan, P Ravi, NY Metaferia, J Li, S AbuHammad, ... Cell reports 38 (1), 2022 | 70 | 2022 |
| Sensitivity of VHL mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway LA Stransky, SM Vigeant, B Huang, D West, T Denize, E Walton, ... Proceedings of the National Academy of Sciences 119 (14), e2120403119, 2022 | 19 | 2022 |
| Transcriptomic correlates of tumor cell PD-L1 expression and response to nivolumab monotherapy in metastatic clear cell renal cell carcinoma T Denize, Y Hou, JC Pignon, E Walton, DJ West, GJ Freeman, DA Braun, ... Clinical Cancer Research 28 (18), 4045-4055, 2022 | 18 | 2022 |
| Seascape Genomics Reveals Metapopulation Connectivity Network of Paramuricea biscaya in the Northern Gulf of Mexico MP Galaska, G Liu, D West, K Erickson, AM Quattrini, A Bracco, S Herrera Frontiers in Marine Science 8, 790929, 2021 | 11 | 2021 |
| PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti–PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients T Denize, OA Jegede, S Matar, N El Ahmar, DJ West, E Walton, ... Clinical Cancer Research 30 (4), 803-813, 2024 | 9 | 2024 |
| Biomarkers of response to first-line nivolumab therapy in patients with advanced renal cell carcinoma (RCC) enrolled in the HCRN GU16-260 trial. N El Ahmar, S Matar, O Jegede, V Savla, A Bagheri Sheshdeh, ... Journal of Clinical Oncology 41 (16_suppl), 4549-4549, 2023 | 2 | 2023 |
| Generation and Characterization of Ex Vivo Expanded Tumor-infiltrating Lymphocytes From Renal Cell Carcinoma Tumors for Adoptive Cell Therapy DJ Einstein, B Halbert, T Denize, S Matar, DJ West, M Gupta, ... Journal of Immunotherapy 47 (9), 361-368, 2024 | | 2024 |
| 47 Generation and Characterization of Ex Vivo Expanded Tumor-Infiltrating Lymphocytes from Renal Cell Carcinoma Tumors for Adoptive Cell Therapy D Einstein The Oncologist 29 (Supplement_1), S26-S27, 2024 | | 2024 |
| Molecular analysis of the HCRN GU16-260-Cohort A phase II study of first-line (1L) nivolumab (nivo) and salvage nivo+ ipilimumab (ipi) in patients (pts) with advanced clear … JP Zaemes, M Hugaboom, V Shah, NB Haas, DF McDermott, O Jegede, ... Journal of Clinical Oncology 42 (16_suppl), 4546-4546, 2024 | | 2024 |
